
With the main end points of incidence of severe neutropenia and alopecia not met in the phase 1b trial of ALRN-6924 for patients with p53-mutated breast cancer, Aileron Therapeutics has decided to end the trial.

With the main end points of incidence of severe neutropenia and alopecia not met in the phase 1b trial of ALRN-6924 for patients with p53-mutated breast cancer, Aileron Therapeutics has decided to end the trial.

In the phase 3 TORCHLIGHT study, survival advantages were shown with the combination of toripalimab and the chemotherapy agent nab-paclitaxel in patients with recurrent/metastatic triple-negative breast cancer treated in Chinese centers.

Results from cohort A of the MagnetisMM–3 trial of erlanatamab for patients with relapsed/refractory multiple myeloma have led the FDA to grant priority review to a biologics license application for the agent in this patient population.

An analysis with longer follow-up of the ZUMA-3 study showed patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with brexu-cel had a median overall survival of 26 months and a complete response plus CR with incomplete count recovery rate of 71%.

In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the full data from the phase 2 trial of panobinostat, gemcitabine, busulfan, and melphalan for patients with high-risk, relapsed/refractory myeloma.

Samer A. Srour, MD, MS, discusses some of the takeaways from the dose-expansion phase of an ongoing phase 1 trial evaluating Orca-Q.

Treatment with an anti-VEGF tyrosine kinase inhibitor appears safe for patients with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

Patients with advanced renal cell carcinoma showed positive improvements in survival and toxicity outcomes when given nivolumab monotherapy, salvage nivolumab, and ipilimumab.

In an interview with Targeted Oncology, John Strickler, MD, discussed the background and goals of the DeFianCe study in the colorectal cancer space.

Moving on to the dose-expansion study of a phase 1b/2a trial of fostroxacitabine bralpamide plus lenvatinib in hepatocellular carcinoma, investigators will assess the recommended phase 2 dose of 30 mg.

Fadi Haddad, MD, discusses the background of a phase 2 study of blinatumomab in combination with ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.

In the PATRIOT-II study, patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance had a complete response rate of 13% and a partial response (PR) rate of 68%.

Treatment with avelumab for locally advanced or metastatic urothelial carcinoma showed to be consistent in a real-world with what was previously seen in the phase 3 JAVELIN Bladder 100 trial.

The secondary analysis of the phase 3 CONDOR study showed that given prior positron emission tomography, piflufolastat F 18 demonstrated changes in intended management, reinforcing the agent's clinical utility.

Based on findings from the phase 2b GT-201 and phase 3 ROMAN trials, the FDA has granted priority review to the new drug application for avasopasem manganese as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer.

Andrew Kuykendall, MD, discusses some of the recent changes there have been for patients with myeloproliferative neoplasms.

The combination of telisotuzumab vedotin and erlotinib did not lead to any unexpected safety signals and showed encouraging antitumor activity in patients with EGFR-mutated, c-Met protein expressing non–small cell lung cancer.

The phase 3 GRAPHITE study showed that vedolizumab plus standard prophylaxis after unrelated allogeneic hematopoietic stem cell transplantation was more effective vs placebo for the prevention of lower gastrointestinal graft-vs-host disease.

Tisagenlecleucel reinfusion shows promise as as an effective bridge to hematopoietic stem cell transplantation in pediatric B-cell acute lymphoblastic leukemia.

Nivolumab and sunitinib combined in the first-line treatment continues to maintain benefit for patients with advanced or metastatic renal cell carcinoma.

A second interim analysis of the phase 3 Karmma-3 trial demonstrated significantly improved progression-free survival and overall response rates, compared with standard regimens, in patients with triple-class-exposed relapsed/refractory multiple myeloma.

The phase 3 ZIRCON trial of 89Zr-DFO-girentuximab in clear cell renal cell carcinoma met its end point by exceeding high sensitivity and specificity thresholds.

Cabozantinib improved outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among poor-risk patients in combination with nivolumab and ipilimumab.

Early data from the phase 2 CaboPoint trial shows a promising response rate among patients with advanced renal cell carcinoma that progressed after checkpoint inhibitor based combination therapy.

Final overall survival data from two arms of the phase 3 IMvigor130 trial display the potential for atezolizumab in addition to chemotherapy for patients with urothelial carcinoma.

Early data of the Orca-T cellular therapy showed enough positive results from patients on the therapy to move on to a phase 3 study in this patient population.

Extended follow-up findings of the phase 3 CheckMate 274 study further support the use of nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma following radical resection.

Pembrolizumab generated antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer, according to cohort B of the phase 2 Keynote-057 trial.

A single-center, retrospective study demonstrated high rates of chronic opioid use after autologous stem cell transplantation in patients with multiple myeloma, also leading to inferior overall survival at 6 months of follow-up.
